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tions (i.e. PIER trial). The model assumes that patients discontinue treatment after the 
second year of treatment. Costs related to drug acquisition, administration, monitor-
ing costs and blindness were considered in the analysis (2015). This model predicted: 
blind-years, quality-adjusted life-years (QALYs), and the direct costs from a payer 
perspective. Results: Treatment without delay was found to be more beneficial 
compared to “with delay” treatment in terms of QALYs (4,487 vs. 4,190) and blind-years 
(1,084 vs. 1,511). The total lifetime cost was calculated to be € 235 higher in patients 
treated without any delay, resulting in an ICER of € 790 per QALY gained (well-below 
the threshold of € 17,000). The higher drug acquisition cost observed in “without delay” 
arm was partially offset by the increased non-medical direct cost related to the “with 
delay” arm. ConClusions: Ranibizumab treatment of wAMD without delay seems 
to be a strongly cost-effective strategy in Greece.
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objeCtives: Chronic spontaneous urticaria (CSU) is characterised by rapid appear-
ance of wheals, angioedema or both, with no obvious cause and with symptoms 
lasting for more than six weeks; CSU has a demonstrable negative impact on patient 
quality of life and societal productivity. The objective of this study was to assess 
the cost-utility of omalizumab compared with continued standard of care (SOC) 
for the treatment of patients with moderate or severe CSU with an inadequate 
response to SOC, from the UK societal perspective. Methods: A Markov model 
was developed, defined by five disease severity health states and three additional 
states for relapse, spontaneous remission and death. The model considered 6 month 
courses of omalizumab treatment, with re-treatment upon relapse (relapse defini-
tion: UAS7≥ 16) and early discontinuation of non-responders (definition of response: 
UAS7≤ 6). Clinical and cost inputs were derived from omalizumab trials and pub-
lished sources; productivity inputs were informed by a non-interventional study 
and average earnings data. The base case considered a 20-year time horizon, and 
cost-utility was expressed as an incremental cost-effectiveness ratio (ICER). Scenario 
analyses included no early discontinuation of non-responders and an altered 
definition of response (UAS7< 16). Results: In the base case analysis, the deter-
ministic ICER was £3,183, with omalizumab being associated with increased costs 
and increased benefit relative to SOC. Probabilistic sensitivity analysis supported 
this result. Individual scenarios without early discontinuation of non-responders 
and adjusting the definition of response had little impact on Results(ICERs £4,409 
and £5,304, respectively). Further sensitivity analyses demonstrated robustness of 
Resultsto changes in key model parameters and inputs. ConClusions: To our 
knowledge, this is the first economic evaluation of omalizumab in CSU from a UK 
societal perspective. Omalizumab was associated with consistently low ICERs across 
a range of different scenarios, demonstrating omalizumab to represent a treatment 
option with societal benefit for CSU in the UK.
PSS48
CoSt-effeCtiveneSS of omalizUmab in ChroniC SPontaneoUS 
UrtiCaria in the netherlandS
Kanters TA1, Gertsen K2, Hakkaart L1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Novartis pharma, Arnhem, The 
Netherlands
objeCtives: Chronic spontaneous urticaria (CSU) is a skin disease, with itchy hives 
that last for at least 6 weeks without an obvious external trigger. Omalizumab has 
been shown to diminish clinical symptoms and signs. The objective of this study 
was to determine the cost-effectiveness of omalizumab relative to cyclosporine 
and standard of care (up to 4 times the daily dose of H1-antihistaminics) for the 
Netherlands. Methods: A Markov model was used in this study. The model’s set-
tings and characteristics of the Dutch patient population were based on an online 
survey among clinical experts. These values were validated during a clinical expert 
committee meeting. The GLACIAL trial was used to describe transition probabilities. 
Data on health care consumption, quality of life and productivity losses were derived 
from medical records and a survey among 93 Dutch CSU patients. Health care con-
sumption was valued using prices from the Dutch costing manual. Utilities were 
derived from EQ-5D and calculated using Dutch tariffs. Productivity losses were val-
ued using Dutch wage rates. Comparator treatments were cyclosporine and standard 
of care. Uncertainty was assessed by one-way sensitivity analyses and probabilistic 
sensitivity analyses. Results: Omalizumab was more effective than cyclosporine 
(incremental QALYs: 11.3). Incremental costs for omalizumab were € 51.052, result-
ing in an ICER of € 4.510 per QALY gained. Compared to standard of care, incremental 
QALYs for omalizumab were 9.2 and incremental costs were € 161.342 (ICER of € 17.502/
QALY gained). Productivity costs played an important role in the value of the ICER. 
Probabilistic sensitivity analyses resembled the Resultsfrom the deterministic analy-
ses. ConClusions: Omalizumab is cost-effective compared to both cyclosporine and 
standard of care. The ICER is well below the implicit cost-effectiveness threshold in 
the Netherlands, which ranges from € 20.000-80.000 per QALY.
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objeCtives: To conduct a cost-utility analysis of ranibizumab versus aflibercept for 
the treatment of patients with visual impairment due to diabetic macular edema 
(DME) in the Greek setting. Methods: A Markov model was adapted to compare the 
use of ranibizumab 0.5mg (pro re nata-PRN and treat & extend-T&E) to aflibercept 
2mg (every 8 weeks after 5 initial doses) in DME. Patients transitioned at a 3-month 
cycle among nine specified health states (including death) over a lifetime horizon. 
Transition probabilities, utilities as well as DME-related mortality incorporated in 
the model were extracted from relative clinical trials, a network meta-analysis and 
other published studies. The drug acquisition and administration costs as well as 
the costs of blindness and laser surgery were also incorporated in the analysis. The 
analysis was conducted from payer perspective and as such only costs reimbursed 
by the payer were considered (year 2014). Treatment costs and health outcomes 
were discounted by 3.5% annually. The incremental cost per quality-adjusted life 
year (QALY) gained and the net monetary benefit was the main outcome measures. 
Sensitivity analysis was conducted to test robustness of the model. Results: Τhe 
use of PRN and T&E ranibizumab regimens were shown to be cost saving compar-
ing to aflibercept by € 2,824 and € 22, respectively, and more beneficial in terms of 
QALYs gained (+0.05) and time without visual impairment (0.031 and 0.034 years), 
thereby dominating aflibercept. Moreover, ranibizumab used as PRN or T&E resulted 
in a net monetary benefit of € 3,984 and € 1,278, respectively. Sensitivity analysis 
revealed that the net monetary benefit for each regimen remained positive for all 
tested scenarios. ConClusions: Both PRN and T&E ranibizumab regimens were 
more beneficial and less costly compared to aflibercept for the management of 
DME. Hence, ranibizumab seems to be a dominant option for the treatment of visual 
impairment due to DME in the Greek setting.
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objeCtives: To estimate the incremental cost utility ratio (ICUR) for ingenol mebu-
tate vs imiquimod 5% for actinic keratosis (AK) patient’s treatment on the face 
and scalp, in Spain. Methods: A Markov model was used to simulate AK patient 
treatment evolution for a 5-year horizon from the Spanish National Health System 
(NHS). Duration of ingenol mebutate treatments was 3 days and 12 days for imiqui-
mod 5%. Effectiveness measure was total clearance rate obtained from indirect 
mixed comparisons (42.24% for ingenol mebutate and 44.54% for imiquimod) and 
adjusted according compliance (90% for ingenol mebutate and 60% for imiquimod). 
Annual recurrence rate (20%) derived from literature. Annual discount rate of 3% 
was applied for costs and outcomes. Total cost estimation (€ ,2015) included: drug 
(retail price VAT included with mandatory deduction), and dermatology visits cost 
(for adverse events and disease management).Utilities values (0.986 for AK and 1 
for clearance) were used to derive quality-adjusted-life years (QALY). Probabilistic 
and deterministic sensitivity analyses were performed to confirm the robustness of 
the obtained results. Results: Ingenol mebutate showed higher effectiveness than 
imiquimod 5%, 0.535 vs 0.503 total gained clearances and 4.451 vs 4.449 total QALYs 
and accounted higher total costs, € 551.50 (46% drug cost) versus € 527.89 (36% drug 
cost) compared to imiquimod 5%. Estimated ICUR was € 10.906/QALY gained with 
ingenol mebutate vs imiquimod 5%. In probabilistic sensitivity analysis performed, 
78% of simulations yielded an ICUR below € 30,000/QALY for ingenol mebutate versus 
imiquimod. ConClusions: Ingenol mebutato vs imiquimod 5% was an efficient 
alternative for NHS for patients with AK, on face and scalp, considering an accept-
able threshold of € 30,000/QALY.
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objeCtives: To examine the impact of delay between indication to treat and injection 
of ranibizumab for the management of age-related macular degeneration (wAMD), in 
Greece. Methods: A Markov model was developed to estimate, in a lifetime horizon, 
the clinical and cost outcomes related to treatment with ranibizumab 0.5mg on a 
pro re nata protocol: a) “without delay” and b) “with delay” between medical indica-
tion and treatment administration. At monthly cycles, patients’ visual acuity could 
increase by 3 lines, remain the same, or decrease by 3 lines. As for the “without delay” 
arm, the number of injections and transition probabilities were obtained from the 
CATT trial, while for the “with delay” arm, a one-month delay at first treatment was 
assumed, based on local experts estimation, and then the delay at re-treatment was 
indirectly modeled by applying number of injections and transition probabilities as 
obtained from clinical trials evaluating the efficacy of a quarterly protocol of injec-
